gallium 68

URGENT ACTION NEEDED: Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772)

Action Requested by November 1, 2019 On October 18, 2019, an opinion piece that NorCal CarciNET Community’s Josh Mailman opinion article (“CMS policy shouldn’t penalize those with rare disease”) was published by The Hill,  The opinion piece highlighted the challenges with the current method that Medicare/CMS use to pay for radiopharmaceuticals. This webpage provides more information on how this will impact NET patients and providers along with a  tool for those that are

There are a number of ways that patients suffering with neuroendocrine tumors and cancer have their disease diagnosed and monitored. Bloodwork The standard marker for neuroendocrine tumors is chromagranin A (sometimes abbreviated Cga). But there are a number of other markers that true neuroendocrine specialists use to help determine disease progression. These tests are things like: Serum Serotonin Neurokinin A Pancreastatin In the case of pancreatic neuroendocrine primaries, tests could

NOLA to offer Gallium 68 Scan Study

NEW ORLEANS – Ochsner Medical Center – Kenner and the New Orleans Neuroendocrine Tumor Specialists (NOLANETS) have launched the Gallium 68 Scan Study to test the effectiveness of this diagnostic tool to detect neuroendocrine tumors. Ochsner – Kenner is the only site from Louisiana through the Florida Panhandle to offer this groundbreaking diagnostic tool in a clinical trial. While most people may not be familiar with rare neuroendocrine tumors, they